Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M22,560Revenue (TTM) $M10,300Net Margin (%)2.5Altman Z-Score1.0
Enterprise Value $M37,122EPS (TTM) $0.5Operating Margin %7.9Piotroski F-Score3
P/E(ttm)82.7Beneish M-Score-2.7Pre-tax Margin (%)1.1Higher ROA y-yN
Price/Book1.910-y EBITDA Growth Rate %13.1Quick Ratio0.6Cash flow > EarningsY
Price/Sales2.15-y EBITDA Growth Rate %7.5Current Ratio0.8Lower Leverage y-yN
Price/Free Cash Flow12.9y-y EBITDA Growth Rate %-19.9ROA % (ttm)1.0Higher Current Ratio y-yN
Dividend Yield %--PEG11.0ROE % (ttm)2.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M535ROIC % (ttm)4.1Gross Margin Increase y-yN

Gurus Latest Trades with MYL

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

MYL is held by these investors:



MYL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BRESCH HEATHER MCEO 2016-08-09Sell100,200$50-15.68view
MAROON JOSEPH C MDDirector 2016-06-03Buy1,670$44.95-6.21view
MAROON JOSEPH C MDDirector 2016-05-25Buy2,370$42.47-0.73view
Cindrich Robert JDirector 2016-05-25Buy1,190$42.47-0.73view
HIGGINS MELINA EDirector 2016-05-12Buy19,900$38.689view
HIGGINS MELINA EDirector 2016-05-06Buy100$38.698.97view
HIGGINS MELINA EDirector 2016-04-28Buy35,000$42.92-1.77view
COURY ROBERT JExecutive Chairman 2016-04-05Sell217,755$45.96-8.27view
MAROON JOSEPH C MDDirector 2016-03-31Buy4,337$46.36-9.06view
PARRISH MARK WDirector 2016-03-17Buy1,705$44-4.18view

Press Releases about MYL :

Quarterly/Annual Reports about MYL:

News about MYL:

Articles On GuruFocus.com
Drug Addiction Treatment Stocks to Watch Feb 22 2017 
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017 
John Paulson's Bargain Stock Jan 30 2017 
Abbott Laboratories: An Undervalued Diamond in Overvalued Markets Jan 24 2017 
Teva: Good Value, Questionable Management? Jan 02 2017 
Integer Investments: Akorn Has 100% Upside Potential Jan 01 2017 
Weak Outlook on Mylan Nov 18 2016 
3 Health Industry Sectors Bound to Profit From a Trump Presidency Nov 11 2016 
Mylan Posts Loss Amid Investigation, Settlement Nov 10 2016 
Buy Health Care Now? It All Depends on the Election Nov 07 2016 

More From Other Websites
Will Mylan, Glaukos, Supernus Live Up To Q4 Growth Views Next Week? Feb 24 2017
Mylan (MYL) to Post Q4 Earnings: Will the Stock Disappoint? Feb 24 2017
Goldman Says Buy Health-Care, Retail Volatility Before Trump Address Feb 22 2017
Where Are the Best Buying Opportunities in Stocks Right Now? Feb 21 2017
Momenta, Pfizer Give Teva Pharma Breathing Room On Generic MS Drug Feb 21 2017
Mylan's Proposed Biosimailar for Cancer Under Review in U.S. Feb 17 2017
Blog Coverage The Biologics License Application for Mylan-Biocon's Proposed Biosimilar -... Feb 17 2017
Trump's pick to lead health agency calls EpiPen issue 'disturbing' Feb 16 2017
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar... Feb 16 2017
Health Care Sector Led the S&P 500’s Rally on February 15 Feb 16 2017
Acorda Must Stave Off Mylan, Teva Generics To Protect Ampyra: RBC Feb 15 2017
Tepper's Appaloosa triples stake in Allergan Feb 15 2017
David Tepper Increases Wagers on Drug Companies Feb 14 2017
Mylan Applauds the Generic Pharmaceutical Association's Rebrand to the Association for Accessible... Feb 14 2017
Mylan Shares Unchanged as Kaleo Releases EpiPen Competitor Feb 14 2017
Company announces pause for drug after price criticism Feb 13 2017
Company announces pause for drug after price criticism Feb 13 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)